Results
eNauka >
Results >
Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
| Title: | Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC | Authors  : | Cho, BC; ...; Secen, Nevena M; ...; (broj, koautora 19) | Issue Date: | 2021 | Publication: | ANNALS OF ONCOLOGY | ISSN: | 0923-7534 Annals of Oncology Search Idenfier |
Type: | Conference Paper | Collation: | vol. 32 str. S1428-S1428 | DOI: | 10.1016/j.annonc.2021.10.217 | WoS-ID: | 000731051400120 | URI: | https://enauka.gov.rs/handle/123456789/823623 | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.